Introduction
Organophosphates are the most widely used pesticide class in crop protection and pest control worldwide [8] . Chlorpyrifos (O,O-diethyl O-(3,5,6-trichloro-2-pyridinyl) ester phosphorothioic acid) is an organophosphate whose great chemical stability and environmental persistence make it a first choice pesticide [35] . Furthermore, chlorpyrifos (CPF) is a broad spectrum pesticide with wide applicability and relative safety to other organophosphates, which has led to its extensive use in agriculture [40] . Indirect exposure to Chlorpyrifos (CPF) can occur through dieting, in both fresh and industrialized food [29] . According to the US Environmental Protection Agency (EPA), the No Observed Adverse Effect Level (NOAEL) of CPF for an acute dietary exposure for inhibition of red blood cell cholinesterase is 0.5 mg/kg/day [18, 46] .
The main mechanism of CPF's acute neurotoxic effects is through acetylcholinesterase (AChE) inhibition and consequent cholinergic hyperstimulation. However, increasing evidence indicates that CPF exerts neurotoxicity at low doses with mechanisms different from those observed at higher doses [17, 42] . It has also been suggested that CPF affects liver [7, 49] ; thyroid [16] ; behavior [28, 41] and reproduction [6, 30] even at levels below toxicity guidelines.
The ability to metabolize CPF appears to be age-dependent in rats, with inferior detoxification in lactating individuals due to their lower metabolic maturity [17, 53] . Thus, exposure to CPF during pregnancy is a critical situation, because the fetuses are a particularly vulnerable subpopulation to chemical contaminants [47] . During pregnancy the fetal neurodevelopment is a complex phe-nomenon that involves several mechanisms and follows a peculiar logic of construction, and gestational exposure to CPF impairs neuronal differentiation, synaptogenesis and gene expression in rats [14] . The rapid development of fetal and infant brain architecture and circuitry is susceptible to exposure to pesticides [21] -even more so when the ability that pesticides have to cross the placental barrier and enter the amniotic fluid [5] , including CPF [26, 27] , is considered. Cell differentiation, plasticity and synapses are variables subject to changes by exposure to pesticides such as CPF [13] .
Studies indicate that organophosphates reduce the neurobehavioral performance and the AchE levels in the serum on the neurodevelopment of children exposed environmentally [1] . Exposure during pregnancy leads to a higher risk of delay in mental and motor development, and to a higher incidence of disorders such as Attention Deficit Hyperactivity Disorder (ADHD) [33] . A previous study has linked prenatal exposure to CPF to a lower weight and smaller head circumference at birth [55] .
It is recognized that the last third of the gestation period is critical for neurogenesis [12] . Brain regions such as the hippocampus and the neocortex develop promptly during this period [45] . The perinatal period presents an intense activity of cerebral circuitry involved with the development and maintenance of appropriate mouse social behavior [21] . Studies on the exposure to CPF during the gestational period show that it features the ability to influence an important neurotransmitter system associated with anxiety modulation -the serotonergic system [44, 48] -in addition to cholinergic system [43] . Thus, it is suggested that CPF is able to induce modifications related to the emotional behavior in the offspring [52] .
Therefore, a new set of relevant mechanisms to the neurotoxicity of CPF, without acting on AChE and in lower doses, promotes great interest in the issue of the security of organophosphates [40] . However, there is little data on the effects of CPF exposure only during pregnancy on the neurodevelopment of the offspring, and on whether these possible effects on the brain circuitry remain during childhood and adulthood. Thus, exposure to low levels of pesticides such as CPF is a concern to be evaluated in pregnancy. Considering these issues, the aim of the present study was to evaluate if gestational exposure to CPF at low doses could induce anxiogenic-like and/or depressive-like behaviors in male offspring after weaning and young adulthood, through behavioral tests for anxiety and depression.
Material and methods

Animals
Wistar rats were provided by the vivarium of the Federal University of Paraná, and kept under controlled conditions of temperature (22 ± 2 • C) with a light/dark cycle of 12 h, and free access to water and food. Female rats were placed into the male cage, at a ratio of 3:1, for 3 h at the end of the dark period. Mating was confirmed by the presence of sperm in vaginal smears, and the day on which sperm was detected was considered gestation day 0 (GD 0). Pregnant females were randomly assigned into 5 groups of 11-14 each.
Maternal weight was monitored daily during treatment period in gestation (GD14-20) and all animals were observed for clinical signs of toxicity. All experiments with pregnant rats and their litters were conducted in accordance to the rules and laws of the Ethics Committee for Research on Animals at UFPR (CEUA/BIO-UFPR; #758/14). All efforts were made to minimize the number of rats and their suffering.
Drugs and treatment
Chlorpyrifos analytical standard (Sigma-Germany, CAS 2921-88-2) was purchased from Sigma Aldrich in Brazil. The CPF doses were based on the value of acceptable daily intake (ADI) of 0,01 mg/kg/day according to the C20 monographic report of the Brazilian national health surveillance agency [3] and to the OECD -407 Guidelines [31] .
Experimental groups were distributed as follows: vehicle control; CPF 0.01 mg/kg/day (CPF 0.01); CPF 0.1 mg/kg/day (CPF 0.1); CPF 1 mg/kg/day (CPF 1); CPF 10 mg/kg/day (CPF 10). The animals were treated orally (gavage). The vehicle used for drug administration in all groups was comprised of 9% saline plus Tween20 (0.1 mL/mL saline), and the volume administered was 3 mL/kg.
Pregnancy outcome
The experimental design is shown in Fig. 1 . The progenitors were treated from day 14-20 of gestation. The behavior tests were performed on postnatal day 21 (PND21) and postnatal day 70 (PND70).
Maternal weight was monitored weekly during lactation. Throughout pregnancy and lactation, animals were observed daily for clinical signs of toxicity related to chemical treatment. The following parameters were evaluated: gestation length, number of implants, post-implantation losses, average weight of offspring, offspring/mother ratio, total live births, pup's stillbirths, and male index in the litter ( Table 1 ). The body mass gain of the mothers was followed during the gestational period of treatment (GD 14-20) (Fig. 2) , as well as, weekly, during lactation.
The offsprings were examined macroscopically at birth. The body weight gain of male offspring was evaluated. The dams that did not deliver viable offsprings were killed on GD 24 for observation of the number of implantations and post-implantation losses.
To evaluate the effects of CPF exposure on the offspring behavior, the male offsprings 1 (PND21) and 3 (PND70) were assessed by modified forced swimming test and open field test, while the offsprings 2 (PND21) and 4 (PND70) were assessed by the elevated plus-maze test (Fig. 1 ) in a number of 8-10 offspring per group.
Elevated plus-maze (EPM) test
The test was conducted as previously described in the literature [19, 32] . On PND21 and PND70, animals were individually placed in the center of the apparatus with the head faced to the open arm, and then they were recorded on camera for 5 min. 
Fig. 2.
Body mass gain of mothers throughout the period of CPF treatment during pregnancy. Two-way ANOVA followed by Dunnett's pot-hoc test for multiple comparisons. * Indicates differences between control group and CPF 10 mg/kg/day group (p < 0.05).
Open field test
To evaluate the influence of the CPF on the locomotor activity of the offsprings, the open field model was used as previously described in the literature [37, 54] . The animal is placed in a rectangular apparatus (40 × 50 × 63 cm) with a division of 9 equal rectangles on the ground. The animal is placed in the center of the apparatus and the number of intersections between these units (crossed rectangles) was evaluated during 5 min as a parameter of locomotor activity. After each animal, the apparatus was cleaned with 20% alcohol solution.
Modified forced swimming test
In order to assess whether the CPF would induce depressive-like behavior, we used the modified forced swimming test [15, 34] . The test is conducted in two steps, the pre-test and the test. During the pre-test the animal is placed in a cylinder (20 cm diameter × 50 cm height containing 30 cm of water at a temperature of 24 ± 2 • C) during 15 min, and 24 h after the pre-test, the animal is again exposed to the test apparatus and recorded during 5 min. The frequency of predominant behavior (immobility, swimming and climbing) was counted at intervals of 5 s. The pre-test was performed on PND20 and PND69, and on PND21 and PND70 the test session was carried. The water was exchanged after each animal. 
Statistical analysis
The normality of the values within the groups was verified by D'agostino & Pearson test. When appropriate, one-way or two-way analysis of variance (ANOVA) was used and the data were expressed as mean ± standard error of the mean (SEM). Dunnett's test was used as a post hoc test for multiple comparisons between the groups. A value of p < 0.05 was defined as significant.
Results
Pregnancy outcome
Between GD14-20, treatment was conducted in all groups, in the same period of the day. During treatment (GD19-21) (Fig. 2) , body mass gain of the mothers for the CPF 10 group was lower than that for the control group. Two-way ANOVA analysis showed that there is statistical interaction on days 19, 20 and 21 [F (28.413) = 2.4 p < 0.05] (Fig. 2) .
All parameters evaluated during pregnancy (Table 1) were similar for the treatment and control groups. Only the index of males born per litter in CPF Group 1 was greater than 50% (57.7%).
The body development of males was also accompanied throughout the postnatal period with notes every 7 days during lactation and every 14 days along the growth phase until PND70 (Fig. 3) . Male body mass gain was significant from PND42 where the CPF 10 group had the greatest mass gain when compared to the control group. Two-way ANOVA analysis showed that there is statistical interaction on evaluation days 42, 56 and 70 [F (28.322) = 3.51 p < 0.05] (Fig. 3) . 
Elevated plus-maze (EPM) test
Open field test
As it can be seen in Table 2 , one-way ANOVA showed a significant difference between the groups (PND21) [F (4.39 = 54.8) p < 0.05]. The Dunnett's post hoc test showed a significant difference between 0.1 groups; 1.0 and 10 mg/kg/day when compared to the control group indicating increased locomotor activity. However, no difference was observed between the all groups in PND70 [F (4.39 = 2.92) p = 0.033].
Modified forced swimming test
One-way ANOVA showed a significant difference between the groups when the immobility and climbing frequencies in the PND21 group were evaluated [F (4.39) = 5.5, p < 0.05; F (4.39) = 3.0, p < 0.05], respectively; see Table 2 , but there was no difference when swimming frequency was evaluated [F (4.39 = 0.61) p < 0.05]. Interestingly, post hoc analysis did not show difference between groups when compared to control groups (p < 0.05).
Regarding PND70, one-way ANOVA showed difference between the groups [F (4.39 = 4.44) p < 0.05], but post hoc test did not show any difference between the frequencies of immobility when compared to control groups (p < 0.05). Also, there was no difference between groups when swimming and climbing frequencies were evaluated [F (4.39) = 2.4, p < 0.05; F (4.39) = 1.8, p < 0.05, respectively]; see Table 2 .
Discussion
The variation in body mass for both mothers and offspring is an indicator of the ability of a toxic influence on pregnancy over body development of the offspring. The dose of 10 mg/kg CPF reduced body mass gain in mothers during treatment (Fig. 2) and increased body weight gain in male offspring from PND42 (Fig. 3) , indicating maternal toxicity. For that dose, other authors have indicated apparent maternal toxicity when the treatment occurred during a similar period (GD14-18), showing that this dose is able to reduce the levels of maternal brain cholinesterase (ChE) [24] . The threshold for the occurrence of gestational weight gain reduction appears to be the dose of 5 mg/kg [20] . Gestational exposures in doses of 0.01, 0.1 and 1 mg/kg were unable to change the weight gain of the mothers during both pregnancy and lactation period when compared to the control group (data not shown). The pregnancy outcomes investigated are also indicators of the pregnancy evolution, showing no adverse effects on maternal parameters (Table 1) . No significant change in the relative weight of liver, kidneys, spleen and brain (mothers and male offspring in PND21 and PND70) was found, suggesting that the doses tested had no influence on these parameters (data not shown).
Differences in the toxicity of CPF between the fetus and the mother have already been reported, showing that for being highly lipophilic the CPF passes easily through the placental barrier [5] . However, the lack of placental CYP450 enzymes group and other esterases is important for the conversion of CPF into chlorpyrifosoxon, which is the most toxic [47] . In this way, the toxicity that was not evidenced in the mother may happen in the fetus.
The evaluation of the male offspring development indicated that all treated groups had a similar body mass gain to the control group until PND42, when the CPF 10 group showed the highest weight gain until the end (PND70). Corroborating with this result, the increased body mass gain of male offspring from PND45 in relation to the control group was observed at a dose of 2.5 mg/kg with maternal exposure to CPF between GD7 and PND21 [25] .
In relation to anxiety, previous studies show the ability of the CPF in changing parameters of type-behavioral anxiety [9, 11, 36, 38] with exposures greater than or equal to 1.0 mg/kg. However, our data show that the CPF could induce an anxiogenic-like behavior at doses of 0.1, 1 and 10 mg/kg/day at the end of lactation (PND21) only with maternal exposure (GD14-20) -when the animals spent a shorter period of time in the open arms when compared to the control group (Fig. 4) . The anxiety-like behavior at the dose of 10 mg/kg/day in PND21 (Fig. 4 ) cannot be completely attributed to the CPF for the fact that this group showed maternal toxicity, with reduction of the mothers weight gain during pregnancy (Fig. 2) . Interestingly, this anxiogenic-like behavior on PND21 in the CPF 0.1, 1 and 10 groups was not evidenced on PND70, suggesting that neuroplasticity throughout the period of life can positively influence the interference caused by exposure to CPF during the gestational phase.
In fact, Icenogle et al. (2004) indicates that exposure to CPF during the period of neurulation (GD9-12) brings locomotor and cognitive impairment but that in the long term the capacity of neuroplasticity can compensate for adverse effects during neurogenesis [22] . Neuroplasticity happens intensively during pregnancy and may suffer the influence of external factors [39] , but may continue to occur throughout life [4, 50] , which added to the conditions of socialization with other animals along the stage of adolescence and early young adult stage can lead to the abolition of the anxiety condition, since unlike the socialization, isolation is a catalyst for the development of anxiety in rats [23] .
It is important to highlight that Venerosi et al. (2010) [51] performed a study using a late gestational exposure (GD [14] [15] [16] [17] to CPF at the dose of 6 mg/kg, and the animals were evaluated at adulthood. Similarly, to our data obtained from PND70, they also did not observe in CD-1 male mice a significant effect on anxiety levels when these animals were evaluated in another animal test of anxiety -the light-dark exploration test. Corroborating with the possibility of reversing the effect of the CPF in adulthood AbouDonia et al. (Table 2) can be related to anxiogenic-like behavior, and discards the motor impairment by CPF.
The behavioral responses related to depression were evaluated using the modified forced swimming test (Table 2 ). In both ages of animals -PND21 and PND70-there was no significant change in the frequencies of immobility, swimming and climbing in all the dosages applied when compared to control groups. That result corroborates data from Venerosi et al. [51] . They have also shown that in adult CD-1 mice exposed to CPF (6 mg/kg) during the late gestational phase (gestational days 14-17) no differences were found between CPF and control mice when they were evaluated in the forced swimming test. Nevertheless, it is important to note that a depressive-like behavior has been reported in previous studies in which animals received the CPF (in different doses) directly by repeated injections (Chen et al. [10] ).
In our study, doses of 0.1, 1 and 10 mg/kg/day could induce an anxiogenic-like behavior in males at the end of lactation, without presenting toxicity in the offspring. Thus, gestational exposure to the CPF in the dose of 0.1 mg/kg/day was considered the low observed adverse effect level (LOAEL) for the anxiogenic-like behavior.
Our results showed the ability of the CPF to influence the mechanisms of neurodevelopment over anxiety-like behavior when exposure occurs only during pregnancy, an intense activity period for the constitution of the central nervous system and in low doses not observed in previous studies. Even more, the occurrence of anxiety-like behavior in the initial stage of neuronal maturation (late lactation) can serve as a window for the consolidation of traumatic events in the future.
Conclusion
In this study, we showed that exposure to low doses of chlorpyrifos during the gestational period (GD14-20) can trigger a condition of anxiety-like behavior in male Wistar rats at the end of the lactation period. Thus, our data suggest that exposure to chlorpyrifos during pregnancy can promote neurological changes in circuit required for the appropriate perceptual effects in the neurodevelopment of the male offspring.
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